These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37234343)

  • 1. Assessment of knowledge, attitude, and practices of acute kidney injury incidence with co-administration of piperacillin/tazobactam and vancomycin among healthcare workers: A cross-sectional study.
    Wali HA; Alabdulwahed MA; Al-Hussain GY; Alabbad MA; Al-Khalaf LH; Alhumaidi SS; Alhussain K; Alomair SM; Almulhim AS
    Saudi Pharm J; 2023 Jun; 31(6):904-910. PubMed ID: 37234343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
    Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
    Blair K; Covington EW
    Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin-tazobactam versus vancomycin cefepime.
    Elliott BP; Tang MM; Madden JA; Markert RJ; Burdette SD; Pleiman CM; Speelmon EC
    Intern Emerg Med; 2022 Jan; 17(1):91-99. PubMed ID: 34089468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients With Obesity.
    Wuerger A; Bowden J; Mitchell A; Marler J
    Hosp Pharm; 2023 Dec; 58(6):605-613. PubMed ID: 38560542
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
    Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
    J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
    Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
    J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
    Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
    Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis.
    Zhang M; Huang L; Zhu Y; Zeng L; Jia ZJ; Cheng G; Li H; Zhang L
    Ann Pharmacother; 2024 Jan; ():10600280231220379. PubMed ID: 38279799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients.
    Traversa A; Hammond DA; Peksa GD; DeMott JM
    J Pharm Pract; 2021 Dec; 34(6):882-887. PubMed ID: 32578474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: An open-label, placebo-controlled, randomized clinical trial.
    Khalili H; Rahmani H; Mohammadi M; Salehi M; Mostafavi Z
    Daru; 2021 Dec; 29(2):341-351. PubMed ID: 34463929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Acute Kidney Injury in Combat-Injured Patients Associated With Concomitant Vancomycin and Extended-Spectrum β-Lactam Antibiotic Use.
    Yabes JM; Stewart L; Shaikh F; Robben PM; Petfield JL; Ganesan A; Campbell WR; Tribble DR; Blyth DM
    J Intensive Care Med; 2021 Jul; 36(7):818-827. PubMed ID: 32508215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.